Should You Buy Organigram (TSX:OGI) Stock Today?

Organigram Holdings’s (TSX:OGI)(NASDAQ:OGI) operations return to growth. Is it time to buy the cannabis stock?

| More on:
Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

The fact that cannabis producer Organigram Holdings (TSX:OGI)(NASDAQ:OGI) delivered a 102% year-over-year net revenue growth for the recently reported first quarter of fiscal 2020 doesn’t move me as much as a 54% sequential sales increase over a recent previous quarter does.

The year-over-year comparison pits one quarter with very little recreational pot sales generated in just one full month and a few weeks of legalization in 2018 against a full three months of consumer cannabis sales in 2019, so the triple-digit growth doesn’t tickle a greedy growth investor’s senses that much today, but that is not the most important part.

A recently reported Q1 2020 net revenue of $25.15 million was 54% higher sequentially and 1.5% better than the $24.75 million reported for the quarter, which ended month end in May last year (OGI’s Q3 2019.)

Although the latest net revenue performance fails to surpass a peak performance of $26.9 million in net sales by February 2019, I would still applaud the company’s recent achievement for one very big reason.

The February 2019 quarter’s revenue reading was potentially heavily inflated, as we later saw a $3.7 million revenue writedown for the fiscal fourth quarter that ended in August. The sum was deducted as provisions for product returns and pricing adjustments on previously invoiced items.

I’d argue that the whole cannabis value chain, down to the retail store, now has a better understanding of customer demand patterns and consumer preferences than it had in, say, December 2018. So, there’s a quite a slim chance that Organigram and peers will make new provisions for product returns on recently sold product going forward.

Therefore, the company’s latest $25.15 million revenue figure is likely more dependable than the nearly $27 million recorded for the December 2018 to February 2019 quarter period due to the customer-knowledge edge gained thus far through the learning curve.

Margins improvement

As expected, the company released a better set of results this time.

The company’s gross margin before fair-value adjustments has recovered to 37% from a low of 5% in a most recent past quarter. I would expect this profitability measure to improve with new edibles and vaporizer product lines after the succesful launches recorded thus far.

Selling, general, and administration expenses have been largely contained at 37% of revenue, and they could shrink further, as economies of scale kick in at higher volumes and revenue levels.

Most noteworthy, Organigram has returned to positive operating margins, as measured by adjusted EBITDA, and that is very encouraging for the company’s profitability prospects. Adjusted EBITDA came in at $4.9 million for the quarter or 19% of net revenue — a strong performance as compared to the past three consecutive quarters.

The return to profitability should be supported by the company’s industry-leading, low-cost-producer profile, where cannabis was produced at a cash cost of $0.61 per gram and “all-in” costs per gram were reported at $0.87 per gram for the quarter, down sequentially from $0.66 and $0.94, respectively.

Time to buy?

The company’s strategic plans remain adequately financed, though at some cost, in terms of dilution, since management embarked on an at-the-money share-issuance program to beef up liquidity. The company still has some lines of credit available to help finance the growing operation.

I’m bullish on the company’s preparedness to launch Cannabis 2.0 products right at the onset, and there could be some promise from its biosynthesis investment, which aims to produce cannabinoids at a fraction of traditional cultivation costs (in direct competition with Cronos Group’s hyped project).

This a unique marijuana stock that could easily become a formidable low-cost leader and survive the competition, even if average pot prices were to decline further, and I expect operating profits to grow from here.

Maybe it’s time to consider taking a bite into this emerging marijuana market winner for its long-term outperformance potential.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends OrganiGram Holdings and OrganiGram Holdings.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »